Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-04
2006-04-04
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C514S342000, C540S460000, C540S467000, C540S474000
Reexamination Certificate
active
07022717
ABSTRACT:
The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.
REFERENCES:
patent: 5021409 (1991-06-01), Murrer et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 6365583 (2002-04-01), MacFarland et al.
patent: 0 434 385 (1991-06-01), None
patent: 0 747 368 (1996-12-01), None
patent: WO 92/16494 (1992-10-01), None
patent: WO 93/12096 (1993-06-01), None
patent: WO 95/18808 (1995-07-01), None
patent: WO 00/02870 (2000-01-01), None
patent: WO 00/45814 (2000-08-01), None
International Search Report based on International Application No. PCT/CA99/00619.
Arenburg et al., “The Role of CXC Chemokines in the Regulation of Angiogenesis in Non-small Cell Lung Cancer”, J. Leukocyte Biol. 62(5):554-562 (1997).
Bleul et al., “The Lymphocyte Chemoattractant SDF-1 is a Ligand for LESTR/Fusin and Blocks HIV-1 Entry”, NATURE, 382(6594): 829-832 (1996).
Boshoff et al., “Angiogenic and HIV-Inhibitory Functions of KSHV-Encoded Chemokines”, SCIENCE, 278(5336):290-294 (1997).
Bridger et al., “Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)-Linked Bis-Tetraazamacrocyles That Inhibit HIV Replication. Effects of Macrocyclic Ring Size and Substituents on the Aromatic Linker”, J. Med. Chem. 38:366-378 (1995).
Bridger et al., “Synthesis amd Structure-Activity Relationships of Phenylenebis(methylene)-Linked Bis-Tetraazamacrocyles That Inhibit HIV Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams”, J. Med. Chem., 39(1):109-119 (1996).
Carroll et al. “Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+T Cells”, SCIENCE, 276(5310):273-276 (1997).
Chemical Abstracts, 113:40649 (1990).
Chemical Abstracts, 111:190197 (1987).
Chemical Abstracts, 123:56538 (1994).
De Clercq et al., “Highly Potent and Selective Inhibition of Human Immunodeficiency Virus by the Byclam Derivative JM3100”, Antimicrobial Agents & Chemotherapy, 38(4):668-674 (1994).
Donzella et al., “AMD3100, A Small Molecule Inhibitor of HIV-1 Entry Via the CXCR4 Co-Receptor”, Nature Medicine, 4(1):72-77 (1998).
Fukuyama et al., “2- and 4-Nitrobenzenesulfonamides: Exceptionally Versatile Means for Preparation of Secondary Amines and Protection of Amines”, Tetrahedron Letters, 36(36):6373-74 (1995).
Gupta et al., “Chemokine Receptors in Human Endothelial Cells”, J. Biological Chem., 273(7):4282-87 (1998).
Hoxie et al., “CD4-Independent Infection by HIV-2 is Mediated by Fusin/CXCR4”, CELL, 87:745-756 (1996).
Joao et al. “Quantitative Structural Activity Relationship Study of Bis-Tetraazacyclic Compounds. A Novel Series of HIV-1 and HIV-2 Inhibitors”, J. Med. Chem. 38:3865-73 (1995).
Leff, “Besides Aiding AIDS Entry, Receptor Honchos Fetal Growth of Brain, Gut, Blood Systems”, Bioworld Today, 9:111 (1998).
Miedema et al., “Changing Virus-Host Interactions in the Course of HIV-1 Infection”, Immunological Reviews, 140:35-72 (1994).
Morphy et al., “Towards Tumour Targeting with Copper-Radiolabelled Macrocycle-Antibody Conjugates: Synthesis, Antibody Linkage, and Complexation Behaviour”, J. Chem. Soc. Perkin Trans., 2:573-85 (1990).
Oberlin et al., “The CXC Chemokine SDF-1 is the Ligand for LESTR/Fusin and Prevents Infection by T-Cell-Line-Adapted HIV-1”, NATURE, 382:833-835 (1996).
Ponath et al., “Chemokine Receptor Antagonists: Novel Therapeutics for Inflammation and AIDS”, Exp. Opin. Invest. Drugs, 7:1-18 (1998).
Schols et al., “Inhibition of T-Tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4”, J. Exp. Med., 186(8):1383-88 (1997).
Schols et al., “Bycyclams, A Class of Potent Anti-HIV Agents, are Targeted at the HIV Coreceptor Fusin/CXCR-4”, Antiviral Research, 35:147-156 (1997).
Tachibana et al., “The Chemokine Receptor CXCR4 is Essential for Vascularization of the Gastrointestinal Tract”, NATURE, 393:591-94 (1998).
Wyatt et al., “The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens”, SCIENCE, 280:1884-88 (1998).
Zou et al., “Function of the Chemokine Receptor CXCR4 in Haematopoiesis and In Cerebellar Development”, NATURE, 393:595-99 (1998).
Boehringer Eva Maria
Bogucki David Earl
Bridger Gary James
Schols Dominique
Skerlj Renato Tony
AnorMED Inc.
Coleman Brenda
Morrison & Foerster / LLP
LandOfFree
Chemokine receptor binding heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor binding heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor binding heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619641